ISRCTN14819975 https://doi.org/10.1186/ISRCTN14819975

# Deferred registration: Quotient Sciences Code: QSC304473

| | | |
|---|---|---|
| **Submission date**<br>30/07/2026 | **Recruitment status**<br>No longer recruiting | [X] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[_] Results<br>[_] Individual participant data<br>[X] Record updated in last year |
| **Registration date**<br>14/08/2026 | **Overall study status**<br>Deferred | |
| **Last Edited**<br>09/09/2026 | **Condition category**<br>Other | |

**Plain English summary of protocol**
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## Contact information

**Type(s)**
Principal investigator

**Contact name**
Dr Philip Evans

**Contact details**
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

**Type(s)**
Public, Scientific

**Contact name**
None Global Clinical Operations

**Contact details**
611 Gateway Boulevard
Suite 900
South San Francisco

San Francisco
United States of America
CA 94080 USA
+1 650 624 1100
clinicaltrials@rigel.com

# Additional identifiers

### Integrated Research Application System (IRAS)
1014407

### CRO Study Code
Quotient Sciences Code: QSC304473

# Study information

### Scientific Title
Quotient Sciences Code: QSC304473 [Full scientific title to be added on or before the deferral expiry date]

### Study objectives
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Ethics approval required
Ethics approval required

### Ethics approval(s)
Approved 21/08/2026, Wales Research Ethics Committee (REC) 2 (Health and Care Research Wales, Castlebridge 5, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44(0) 2920 785738; Wales.REC2@wales.nhs.uk), ref: 26/WA/0178

### Primary study design
Interventional

### Allocation
N/A: single arm study

### Masking
Open (masking not used)

### Control
Uncontrolled

### Assignment
Single

### Purpose
Phase I trial in healthy volunteers

### Study type(s)

### Health condition(s) or problem(s) studied
Healthy volunteers

### Interventions
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Intervention Type
Drug

### Phase
Phase I

### Drug/device/biological/vaccine name(s)
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Primary outcome(s)
1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Key secondary outcome(s)

### Completion date
02/10/2026

## Eligibility

### Key inclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Healthy volunteers allowed
Yes

### Age group
Mixed

### Lower age limit
30 Years

### Upper age limit
65 Years

### Sex
Male

### Total final enrolment
0

### Key exclusion criteria
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### Date of first enrolment
25/08/2026

### Date of final enrolment
02/10/2026

## Locations

### Countries of recruitment
United Kingdom

England

### Study participating centre
**Quotient Sciences Limited**
Mere Way
Ruddington Fields
Ruddington
Nottingham
England
NG11 6JS

## Sponsor information

### Organisation
Rigel Pharmaceuticals, Inc.

## Funder(s)

### Funder type

### Funder Name
Rigel Pharmaceuticals, Inc.

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary
Not expected to be made available